RxDoctor Payments DataLook up a doctor →

Darek Eggleston, DO

Family Medicine · Pleasant View, UTNPI 1518302850

Payments from drug & device makers

$2,816,366in general payments, 2019–2025

Across 993 payments — averaging $2836.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Modernatx, Inc.$1.7M
  • Novavax Inc$487K
  • Genentech, Inc.$416K
  • Abbott$119K
  • AstraZeneca$106K
  • GSK$18K
  • plus $13K from 43 others

What the payments were for

  • Travel & lodging$1,71631%
  • Food & beverage$3,69967%
  • Education$1002%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,816,366 in reported general payments places this provider in the 95th percentile of 928 family medicine providers in Utah.

See all family medicine providers in Utah

Medicare billing

Part B allowed, 2024
$44,352
Medicare patients
136
Services billed
1,141

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide100$101,051
XareltoRivaroxaban36$39,875
JardianceEmpagliflozin20$26,442
FarxigaDapagliflozin Propanediol19$25,046
EliquisApixaban27$24,535
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$21,174
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog13$13,899
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$11,583
GlyxambiEmpagliflozin/Linagliptin12$9,720
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog24$7,431
MyrbetriqMirabegron12$6,282
ShingrixVaricella-Zoster Ge/As01b/Pf32$5,669
Omeprazole134$2,059
Gabapentin91$1,881
Levothyroxine Sodium164$1,787

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$92$101,051100 claims
Johnson & JohnsonXarelto$63$39,87536 claims
AstraZenecaFarxiga, Breztri Aerosphere$106,342$36,62933 claims
GSKTrelegy Ellipta, Shingrix$18,027$26,84450 claims
PfizerEliquis$326$24,53527 claims
Astellas Pharma US IncMyrbetriq$398$6,28212 claims
AbbVieSynthroid$457$1,36813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 928 family medicine providers in Utah.

Other family medicine in Pleasant View

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →